Riverdale, NY1 Active Studies

Myalgic Encephalomyelitis Clinical Trials in Riverdale, NY

Find 1 actively recruiting myalgic encephalomyelitis clinical trials in Riverdale, NY. Connect with local research sites and explore new treatment options.

1
Active Trials
1
Sponsors
2,000
Enrolling

Recruiting Myalgic Encephalomyelitis Studies in Riverdale

About Myalgic Encephalomyelitis Clinical Trials in Riverdale

Myalgic encephalomyelitis (ME/CFS) is a complex, chronic illness characterized by profound fatigue, post-exertional malaise, cognitive impairment, and sleep dysfunction. It affects millions worldwide and has no definitive diagnostic test or cure. Research is exploring immune, metabolic, and neurological mechanisms.

There are currently 1 myalgic encephalomyelitis clinical trials recruiting participants in Riverdale, NY. These studies are seeking a combined 2,000 participants. Research is being sponsored by Albert Einstein College of Medicine. Clinical trial participation is free and participants receive study-related medical care at no cost.

Myalgic Encephalomyelitis Clinical Trials in Riverdale — FAQ

Are there myalgic encephalomyelitis clinical trials in Riverdale?

Yes, there are 1 myalgic encephalomyelitis clinical trials currently recruiting in Riverdale, NY. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Riverdale?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Riverdale research site will contact you about next steps.

Are clinical trials in Riverdale free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Riverdale studies also compensate for your time and travel.

What myalgic encephalomyelitis treatments are being tested?

The 1 active trials in Riverdale are testing new therapies including novel drugs, biologics, and treatment approaches for myalgic encephalomyelitis.

Data updated July 17, 2026 from ClinicalTrials.gov